Loading...
Loading...
GTHX| Name | Value |
|---|---|
| Revenues | 42.4M |
| Cost of Revenue | 1.4M |
| Gross Profit | 41.0M |
| Operating Expense | 29.5M |
| Operating I/L | 11.5M |
| Other Income/Expense | -1.5M |
| Interest Income | 0.6M |
| Pretax | 10.0M |
| Income Tax Expense | 1.3M |
| Net Income/Loss | 8.7M |
G1 Therapeutics, Inc. is a clinical-stage biopharmaceutical company specializing in the development and commercialization of small molecule therapeutics for cancer treatment. The company's flagship product, COSELA, is designed to reduce chemotherapy-induced myelosuppression in adult patients with extensive stage small cell lung cancer. Additionally, G1 Therapeutics is advancing trilaciclib, a CDK 4/6 inhibitor, and lerociclib, an oral CDK4/6 inhibitor, for various oncology indications. The company also has a Phase IIa clinical trial for rintodestrant, an oral selective estrogen receptor degrader, targeting estrogen receptor-positive and HER2-negative breast cancer. G1 Therapeutics generates revenue through the development and commercialization of these innovative cancer therapeutics.
